Vanguard S&P Mid-Cap 400 Growth ETF (IVOG)

The Vanguard S&P Mid-Cap 400 Growth ETF (ticker: IVOG) is an exchange-traded fund that holds the growth-oriented companies within the S&P Mid-Cap 400 index — a focused portfolio of roughly 200 mid-sized American corporations selected for above-average earnings or sales growth expectations.

The index and its construction

IVOG is built on the S&P MidCap 400 Growth Index, which begins with the 400 stocks that make up the broader S&P MidCap 400 — the middle tier of the U.S. market by capitalization, sitting between the large-cap S&P 500 and the small-cap Russell 2000. From that universe of 400, the index methodology splits the companies into growth and value categories based on a suite of measures: expected earnings growth, sales growth, and price-to-book and price-to-earnings multiples. IVOG holds the half designated as growth-oriented, typically around 200 names.

The result is a portfolio concentrated in industries where growth matters most — technology, healthcare, and consumer discretionary companies dominate. Industrials, financials, and energy appear, but less prominently. Because the index screens for growth characteristics rather than assigning stocks arbitrarily, the IVOG portfolio consists of actual operating businesses with momentum: a medical-device maker expanding abroad, a software firm gaining market share, a retailer proving its digital strategy. That focus means IVOG tends to outperform the broader mid-cap market during expansions and underperform during downturns.

Size and liquidity

IVOG is moderately traded in dollar volume, with a spread (the difference between buy and sell prices) that widens and narrows with market conditions but is tight enough that most retail and institutional traders can get in and out without significant friction. The fund holds a specific, published basket of 200 stocks, so its price converges closely to its underlying net asset value; arbitrage keeps tracking error minimal.

The typical holding is a company with a market capitalization in the $2 billion to $10 billion range — large enough to have real scale and analyst coverage, small enough to still have room to grow. This size sweetspot has historically seen less attention from passive mega-funds than larger-cap stocks and sometimes less efficiency in pricing, which can create pockets of opportunity. It also means individual holdings matter more to returns than they would in a 500- or 1000-stock fund: a top-10 position might represent 2 or 3 percent of the portfolio, so a single company’s stumble is felt.

Where IVOG fits in a portfolio

Investors use IVOG in different ways. Some treat it as a core holding for U.S. equity exposure, preferring growth-tilted mid-caps to a plain vanilla broad market fund. Others use it as a satellite position to tilt a diversified portfolio toward growth and mid-size companies. Because mid-caps have different risk and return characteristics than large-caps — they are more volatile and more growth-sensitive but potentially higher-returning over long stretches — pairing IVOG with large-cap and small-cap holdings can smooth a portfolio’s behaviour.

The growth tilt is not automatic. During years when investors reward value and income over expansion, IVOG lags. During booms, it often leads. Its fortunes are tied to confidence in future corporate earnings and appetite for companies that prize growth over dividends and stability.

How to research IVOG

Start with the fund’s fact sheet, which lists the current holdings, sector weights, and the most recent performance versus its benchmark. Because IVOG is run by Vanguard and uses a rules-based index, its prospectus is straightforward and its methodology transparent — the S&P Mid-Cap 400 Growth Index prospectus spells out exactly how stocks are classified as growth.

For context on what you own, the annual reports of a handful of the top 10 holdings reveal the kinds of businesses you are betting on. Since the portfolio turns over slowly (the index reconstitutes quarterly and growth classification is relatively stable), a holding from last year is likely still there. Comparing IVOG’s returns and drawdowns to the S&P MidCap 400 (the value-included version) shows the price of growth tilting — the volatility you accept and the upside you pursue in exchange for more sensitivity to recession and rotation.